Wow,

If you do not know "What is the question?"; IMO your stated investments in Cardiogenics are at greater risk than any other Cardiogenics shareholder as you apparently fail to understand Dr G's statement in their December 2011 Press Release -

"This study is a crucial step in confirming our current laboratory data from the QL Care Analyzer in a clinical setting," said Dr. Yahia Gawad, CEO of CardioGenics. "The findings will support our path towards the FDA submission. We will provide an update on the QL Care beta testing process, once it has been approved."

In reply to your statement "...what information would you expect the company to release?"; I want Cardiogenics to publicly explain two things

1. What has delayed the approval of the beta testing process (conducting the head-to-head study) for almost 500 days?
2. What is the timeline and plan for the Company to complete the head-to-head study and to raise requisite funding to ensure the Company remains a going concern.

Ante